Consistent with the level of FSTL1 in the liver, the expression of its receptors was decreased in the liver from patients with NASH in our study as well as in other studies41 (Fig. 7h, i, Supplementary Fig. 11). Here, FSTL1 is linked to metabolic dysfunction-associated steatohepatitis.